Drugs / BS006
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05938296 | Dec 2023 → Dec 2026 | cancer | Binhui Biopharmaceutical Co., Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT05393440 | Sep 2022 → Dec 2023 | cervical cancer | Zhongnan Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07382531 | Sep 2023 → Dec 2027 expected | cancer | Binhui Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BS-006 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05393440 ↗ |
| Route | Other | “Intratumoral Injection” NCT05393440 ↗ |